{
  "patent_number": "US 8889135",
  "country": "US",
  "title": "How Dosing Humira for Rheumatoid Arthritis Works",
  "original_title": "Methods of administering anti-TNFα antibodies",
  "summary": "This patent defines the specific 40mg biweekly injection schedule for the drug Humira to treat rheumatoid arthritis.",
  "what_it_does": "The patent claims a specific treatment regimen for rheumatoid arthritis using a human anti-TNFα antibody. It mandates a 40 mg dose delivered subcutaneously (under the skin) once every 13 to 15 days. The antibody must contain specific amino acid sequences in its variable light and heavy chain regions, which are the parts of the protein that bind to the target molecule. By blocking TNFα, a protein involved in inflammation, the treatment aims to reduce the symptoms of the disease.",
  "what_it_does_not_cover": [
    "Does not cover the use of this antibody for conditions other than rheumatoid arthritis.",
    "Does not cover dosing schedules that fall outside the 13-15 day window.",
    "Does not cover doses other than 40 mg.",
    "Does not cover antibodies that lack the specific amino acid sequences defined in the claims."
  ],
  "filed": "2002-06-05",
  "granted": "2014-11-18",
  "expires": null,
  "status": "active",
  "holder": "AbbVie Biotechnology Ltd",
  "holder_url": "https://patentbrief.org/company/abbvie-biotechnology-ltd",
  "inventors": [
    {
      "name": "Steven A. Fischkoff",
      "url": "https://patentbrief.org/inventor/steven-a-fischkoff"
    },
    {
      "name": "Joachim Kempeni",
      "url": "https://patentbrief.org/inventor/joachim-kempeni"
    },
    {
      "name": "Roberta Weiss",
      "url": "https://patentbrief.org/inventor/roberta-weiss"
    }
  ],
  "times_cited": 15,
  "tags": [
    "biotech",
    "pharmaceutical"
  ],
  "abstract": "Methods of treating disorders in which TFNα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.",
  "url": "https://patentbrief.org/patent/us/8889135/humira-biosimilar-barrier",
  "markdown_url": "https://patentbrief.org/patent/us/8889135/humira-biosimilar-barrier/md",
  "google_patents_url": "https://patents.google.com/patent/US8889135",
  "relatedPatents": []
}